Comparative Pharmacology
Head-to-head clinical analysis: ELINEST versus MIRCETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ELINEST versus MIRCETTE.
ELINEST vs MIRCETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethinyl estradiol is an estrogen; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity. The combination suppresses gonadotropins, inhibiting ovulation.
Combination of ethinyl estradiol and desogestrel; estrogen and progestin inhibit gonadotropin release, suppressing ovulation and altering cervical mucus and endometrial receptivity.
0.5 mg orally once daily.
One tablet daily for 21 days, followed by 7 placebo tablets. Each active tablet contains 0.015 mg ethinyl estradiol and 2 mg chlormadinone acetate. Route: oral.
None Documented
None Documented
Terminal elimination half-life of estradiol (E2) is ~13-16 h, but due to the prodrug nature and accumulation of estrogen metabolites, the effective half-life during continuous use is ~36 h, supporting once-daily dosing.
Desogestrel active metabolite etonogestrel: 21-24 hours; ethinyl estradiol: 12-14 hours
~68% renal (50% unchanged, ~18% as inactive metabolites), ~30% biliary/fecal, with enterohepatic recycling of drug and estrogen conjugates.
Urine (50-60% as metabolites, <10% unchanged), feces (30-40% as metabolites)
Category C
Category C
Oral Contraceptive
Oral Contraceptive